The evolving role of telomerase inhibitors in the treatment of cancer

References

• Mokbel K. The role of telomerase in breast cancer. Eur J Surg Oncol 2000;26:509–14
   PubMedGoogle Scholar
• Zhu J, Wang H, Bishop J, Blackburn E. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci USA 1999;96:3723–8
   PubMed Web of Science ®Google Scholar
• Mokbel K, Parris CN, Ghilchik M, Williams G, Newbold RF. The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer. Am J Surg 1999;178: 69–72
   PubMed Web of Science ®Google Scholar
• Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999;96:5147–52
   PubMed Web of Science ®Google Scholar
• Kirkpatrick KL, Mokbel K. The significance of human telomerase reverse transcriptase (hTERT) in cancer. Eur J Surg Oncol 2001;27:754–60
   PubMedGoogle Scholar
• Le S, Moore J, Haber J, Greider C. RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics 1999;152:143–52
   PubMed Web of Science ®Google Scholar
• Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236–41
   PubMed Web of Science ®Google Scholar
• Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, et al. A mammalian telomerase-associated protein. Science 1997;275:973–7
   PubMed Web of Science ®Google Scholar
• Murakami J, Nagai N, Shigemasa K, Ohama K. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 1999;35:1027–34
   PubMed Web of Science ®Google Scholar
• Fletcher TM, Cathers BE, Ravikumar KS, Mamiya BM, Kerwin M. Inhibition of human telomerase by 7-deaza-2’-deoxyguano-sine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2’-deoxyguanosine 5’-triphosphate. Bioorg Chem 2001;29: 36–55
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Takahashi Y, Shinohara A, et al. The 5’-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem Biophys Res Commun 2000;273:316–21
   PubMed Web of Science ®Google Scholar
• Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Invest Drugs 2001;10:2117–40
   PubMed Web of Science ®Google Scholar
• Chou WC, Hawkins AL, Barret JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001;108:1541–7
   PubMed Web of Science ®Google Scholar
• Herbert BS, Pongracz K, Shay JW, Gryaznov SM. Oligonucleotide N3’-P5’ phosphoramidate as efficient telom-erase inhibitors. Oncogene 2002;21:401–10
   Google Scholar
• Chen Z, Monia PB, Corey DR. Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2’-O-Methoxyethyl oligonucleotides. J Med Chem 2002;45: 5423–5
   PubMed Web of Science ®Google Scholar
• Gryaznov SM, Pongracz K, Matray T, et al. Telomerase inhibitors: oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotide Nucleic Acids 2001;20:401–10
   PubMed Web of Science ®Google Scholar
• Kondo Y, Koga S, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2–5A-anti-telomerase RNA component. Oncogene 2000;19:2205–11
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Takahashi Y, Shinohara A, et al. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 1998;58:5406–10
   PubMed Web of Science ®Google Scholar
• Ren J, Qu X, Dattagupta N and Chaires JB. Molecular recognition of a RNA:DNA hybrid structure. J Am Chem Soc 2001;123:6742–3
   Google Scholar
• Guiducci C, Cerone MA, Bacchetti S. Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene 2001;20:714–25
   PubMed Web of Science ®Google Scholar
• Koga S, Hirohata S, Kondo Y, et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000;11:1397–1406
   PubMed Web of Science ®Google Scholar
• Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Med 2000;6:1011–17
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Migliaccio M, Guillaume P, et al. Lack of tumor recognition by hTERT peptide 540–548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001;31:2642–51
   PubMed Web of Science ®Google Scholar
• Gowan SM, Heald R, Stevens MF, Kelland LR. Potent inhibition of telomerase by small pentacyclic acridines capable of interacting with G-quadruplex. Mol Pharmacol 2001;60:981–8
   PubMed Web of Science ®Google Scholar
• Sidorov IA, Hirsch KS, Harley CB, Dimitrov DS. Cancer treatment by telomerase inhibitors: predictions by a kinetic model. Math Biosci 2003;181:209–21
   PubMed Web of Science ®Google Scholar